Meeting four emerging expectations for the life sciences industry

Streamlining processes at life sciences organizations has always been crucial, and with economic pressures, it has become more imperative than ever. To effectively address potential challenges such as disparate processes and siloed functions, these organizations must standardize their processes and refine their operations to achieve optimal data processing without adding resources. 

The solution lies in embracing an integrated Global Business Services (GBS) model enabled by ServiceNow for life sciences companies. The GBS model serves as a strategic solution to drive operational efficiency, optimize processes, enhance productivity, and simultaneously reduce costs—aligning with the core priorities of CEOs seeking to improve efficiency and elevate user and customer experience.

Increasing operational productivity is emerging as a key objective for CXOs across life science organizations. The key ask is to make their business models leaner, more flexible, and more robust. Amid a vast ecosystem of processes, systems, and resources, it is imperative that these leaders have visibility into how each piece layers, connects, and cooperates to ultimately bring a pharmaceutical product or solution into market.  

The solution lies in simplifying processes and automating activities for life science companies by orchestrating workflows in ServiceNow. This thereby accelerates research, lead time, seamless collaboration, and onboarding as well as real-time reporting of information for executive visibility and decision-making.

Manufacturing consistently holds a significant and indispensable role within the life sciences industry. Managing manufacturing operations in this sphere revolves around three priorities: 1) optimal manufacturing conditions maintenance; 2) accelerating time-to-market; and 3) ensuring quality, regulatory adherence, and safety.

To address these priorities, it is imperative to develop solutions that minimize uncertainty and amplify reliability in life sciences manufacturing operations—while simultaneously trimming operational costs and upholding regulatory adherence. To solve for this, Deloitte and ServiceNow can power enhanced asset performance, vendor management, and improved visibility and traceability.

In an environment as highly regulated as the pharmaceutical industry, FDA and GxP compliance is an utmost necessity. These stringent compliance regulations have bred a foundational need for life sciences organizations to know the entire history of each piece of equipment across their processes and situate them in secure, auditable, and traceable environments. But too often, they are uncovering this critical information manually or with laggard systems, leaving room for error and impeding efficiency. 

Everything your organization seeks to protect from a cyber and risk perspective can be monitored with support from Deloitte in ServiceNow. As both a workflow system and a source of record for troves of data, ServiceNow is uniquely positioned to help organizations maintain visibility of compliance, from tracking actions to producing audit records.

Through a cross-functional, life-sciences-specific solution that connects teams and work across sectors (e.g., commercial, R&D, manufacturing, compliance, and GBS)

Across a common platform to launch services and work with a library of accelerated life-sciences-specific workflows.

Via an engagement layer for internal and external stakeholders (from employees to patients to payers) and “front door” experience available on tablets for field and lab work

That drives productivity through ServiceNow Now Assist in Virtual Agent, process bionics, robotic process automation, and pre-configured, life-sciences-specific integrations with core source systems, such as Veeva, and other laboratory management and clinical trial systems

With a repeatable and scalable platform that is easily extended and enabled for citizen development—facilitating faster speed to value and a lower cost to maintain.